Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/32356
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorEscorial, Mónica-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorAgulló, Laura-
dc.contributor.authorZandonai, Thomas-
dc.contributor.authorMargarit, César-
dc.contributor.authorMorales, Domingo-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T10:54:53Z-
dc.date.available2024-06-27T10:54:53Z-
dc.date.created2024-04-12-
dc.identifier.citationMinerva Anestesiologica. 2024 May;90(5):386-396.es_ES
dc.identifier.issn0375-9393-
dc.identifier.issn1827-1596-
dc.identifier.urihttps://hdl.handle.net/11000/32356-
dc.description.abstractBACKGROUND: opioids are widely used in chronic non-cancer pain (cNcP) management. However, they remain controversial due to serious risk of causing opioid use disorder (oUD). our main aim was to develop a predictive model for future clinical translation that include pharmacogenetic markers. METHODS: an observational study was conducted in 806 pre-screened spanish cNcP patients, under long-term use of opioids, to compare cases (with oUD, N.=137) with controls (without oUD, N.=669). Mu-opioid receptor 1 (OPRM1, a118g, rs1799971) and catechol-O-methyltransferase (COMT, g472a, rs4680) genetic variants plus cytochrome P4502D6 (cYP2D6) liver enzyme phenotypes were analyzed. socio-demographic, clinical and pharmacological outcomes were also registered. a logistic regression model was performed. the model performance and diagnostic accuracy were calculated. RESULTS: OPRM1-AA genotype and cYP2D6 poor and ultrarapid metabolizers together with three other potential predictors: 1) age; 2) work disability; 3) oral morphine equivalent daily dose (MeDD), were selected with a satisfactory diagnostic accuracy (sensitivity: 0.82 and specificity: 0.85), goodness of fit (P=0.87) and discrimination (0.89). Cases were ten-year younger with lower incomes, more sleep disturbances, benzodiazepines use, and history of substance use disorder in front of controls. CONCLUSIONS: Functional polymorphisms related to OPRM1 variant and cYP2D6 phenotypes may predict a higher OUD risk. Established risk factors such as young age, elevated MEDD and lower incomes were identified. A predictive model is expected to be implemented in clinical setting among cNcP patients under long-term opioids use.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent16es_ES
dc.language.isoenges_ES
dc.publisherEDIZIONI MINERVA MEDICAes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectchronic paines_ES
dc.subjectanalgesicses_ES
dc.subjectopioides_ES
dc.subjectopioid-related disorderses_ES
dc.subjectPharmacogeneticses_ES
dc.subjectPredictive value of testses_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleClinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approaches_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.contributor.instituteInstitutos de la UMH::Instituto de Bioingenieríaes_ES
dc.contributor.instituteInstitutos de la UMH::Instituto Centro de Investigación Operativaes_ES
dc.relation.publisherversionhttps://doi.org/10.23736/S0375-9393.24.17864-9es_ES
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica


Vista previa

Ver/Abrir:
 Clinical prediction of opioid use disorder in chronic pain patients. A cohort-retrospective study with a pharmacogenetic approach.pdf

2,15 MB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.